Month: April 2025
Excerpt from the Press Release: PALO ALTO, Calif., April 16, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, following the formation of its proposed joint venture with IPMC Company,…
Read More
TrialStat will be showcasing our cutting-edge EDC Platform with integrated Medical Imaging Platform at the COG New England Meeting in Burlington, Massachusetts on April 28th – 30th. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing clinical research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Read More
The Cancer Therapeutics Innovation Pipeline (CTIP) Program was established to capitalize on Ontario’s expertise in cancer biology and drug discovery. Its aim is to create a pipeline of validated cancer targets and First-in-Class (FiC) or Best-in-Class (BiC), novel, selective lead molecules (small molecules or biologics) that will attract partnerships and/or investment for further preclinical and…
Read More
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in inflammation, in both rheumatology and dermatology, including rheumatoid arthritis and atopic dermatitis Nurix to receive a $5 million milestone payment from…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ — Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa Therapeutics Inc. (Nasdaq: ATOS). The collaboration leverages Nona’s proprietary H2L2…
Read More
Excerpt from the Press Release: SAN DIEGO, April 9, 2025 /PRNewswire/ — Long COVID or post COVID-19 syndrome, is a clinical entity observed in certain patients wherein symptoms of illness persist for at least several weeks or months after Covid19 infection. While the etiology of this clinical entity is not fully understood, it is likely…
Read More
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve…
Read More
Excerpt from the Press Release: TORONTO — A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes and obesity medications — including Ozempic, Wegovy and Mounjaro — that have changed the lives of millions of people around the world. Dr. Daniel Drucker, an endocrinologist and…
Read More
Excerpt from the Press Release: SAN FRANCISCO, April 1, 2025 /PRNewswire/ — Shanghai Yingli Pharmaceutical Co., Ltd. (Yingli Pharma), a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune diseases, announced today that it has received clearance from the US Food and Drug Administration (FDA) to initiate a global registration…
Read More
TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete…
Read More